Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions

Inclusion Criteria: * Healthy adult male or female volunteers, 18-45 years of agestart of the study. * Other birth control methods may be deemed acceptable * Postmenopausal women with amenorrhea for at least 2 years will be eligible * Voluntarily consent to participate in the study Exclusion Criteria: * History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease * In addition, history or presence of: * alcoholism or drug abuse within the past year * hypersensitivity or idiosyncratic reaction to Loratadine or any other H1-receptor antagonist * hypersensitivity or idiosyncratic reaction to Pseudoephedrine or any other sympathomimetic amines * Glaucoma or hypermetropia * Subjects receiving a monoamine oxidase (MAO) inhibitor or within 14 days of stopping use of an MAO inhibitor, or any sympathomimetic amines * Subjects who have used any drugs or other substances known to be strong inhibitors of CYP (cytochrome P450) enzymes within 10 days of study start * Subjects who have used any drugs or other substances known to be strong inducers of CYP (cytochrome P450) enzymes within 28 days of study start * Female subjects who are pregnant or lactating * Subjects who have been on an abnormal diet (for whatever reason) during the 28 days prior to the first dose * Subjects who, through completion of the study, would have donated in excess of: * 500 mL of blood in 14 days * 500-750 mL of blood in 14 days (unless approved by the principal Investigator) * 1000 mL of blood in 90 days * 1250 mL of blood in 120 days * 1500 mL of blood in 180 days * 2000 mL of blood in 270 days * 2500 mL of blood in 1 days * Subjects who have participated in another clinical trial within 28 days prior to the study start